SCHEMBL4076924

SCHEMBL4076924

Cc1cc(N(C)C)c2cc(C3=NC(c4ccc5nc(C)cc(N(C)C)c5c4)N(N)C(NCCCN(C)C)=N3)ccc2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.35
TRIM58 Q8NG06 3/20 0.34
RAD52 P43351 3/20 0.33
HTT P42858 1/20 0.33
NQO2 P16083 2/20 0.33
NCF1 P14598 1/20 0.33
POLB P06746 3/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32
SLC2A1 P11166 1/20 0.32
APOBEC3A P31941 1/20 0.32
RAB9A P51151 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
TOP2A P11388 1/20 0.32
ALDH1A1 P00352 2/20 0.31
SYK P43405 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4081905 0.86 TERT (0.35) TERTHTT
SCHEMBL6595991 0.85 TERT (0.36) TERT
SCHEMBL6596676 0.82 HSD17B10 (0.33) TERTKMT2ANPC1RAB9AALDH1A1
SCHEMBL4076925 0.81 TERT (0.44) TERT
SCHEMBL4076912 0.80 TLR9 (0.37) TERT
SCHEMBL4077098 0.80 TERT (0.52) TERTKMT2ARAC1
SCHEMBL4073299 0.78 TERT (0.38) TERT
SCHEMBL6591886 0.78 BRD4 (0.37)
SCHEMBL4081860 0.76 TERT (0.34) TERT
SCHEMBL4074857 0.75 TERT (0.35) TERTRAD52ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US claimed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US claimed
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS AVENTIS PHARMA S.A. (FR) 2009-09-10 US disclosed
US-7482352-B2 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2009-01-27 US disclosed
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US disclosed
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-03-31 US disclosed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent DNASE1L3, SERPINB1, BRDT TERT 43/4885TRIM58 2186/4885RAD52 1035/4885
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS DPYD, NTPCR, NME1 TERT 196/4885TRIM58 3088/4885RAD52 1606/4885
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents DPYD, NTPCR, NME1 TERT 196/4885TRIM58 3088/4885RAD52 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.